Search

Your search keyword '"Claudio De Magistris"' showing total 6 results
Start Over Author "Claudio De Magistris"
6 results on '"Claudio De Magistris"'

1. Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data

Author

Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, Roberta Della Pepa, Alessandro Gozzetti, Velia Bongarzoni, Antonio Maroccia, Valeria Amico, Paola Stefanoni, Elena Zamagni, Sofia Terlizzi, Daniele Derudas, Salvatore Palmieri, Rosario Bianco, Concetta Conticello, Marino Brunori, Angela Rago, Flavia Lotti, Raffaele Fontana, Nicola Sgherza, Elena Rossi, Anna Maria Cafro, Massimiliano Arangio Febbo, Angela Maria Quinto, Claudio Cerchione, Gloria Margiotta Casaluci, Annalisa Citro, Catello Califano, Renato Zambello, Silvia Mangiacavalli, Carmine Liberatore, Gabriele Buda, Claudio De Magistris, Angela Amendola, Ernesto Vigna, Antonella Bruzzese, Emiliano Barbieri, Micol Quaresima, Daniela Roccotelli, Francesca Farina, Jacopo Micozzi, Iolanda Donatella Vincelli, Giuseppe Tarantini, Elisabetta Antonioli, Sara Aquino, Alessandro Maggi, Alessandra Lombardo, Giuseppe Bertuglia, Anna Furlan, Anna Mele, Ombretta Annibali, Emilia Cotzia, Pietro Benvenuti, Lorenzo De Paoli, Gregorio Barilà, Sonia Morè, Valerio De Stefano, Francesco Di Raimondo, Maria Teresa Petrucci, Niccolò Bolli, Pellegrino Musto, Antonino Neri, Fortunato Morabito, Giovanni Tripepi, and Massimo Gentile

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Not available.

Published
2025
Full Text
View/download PDF

2. Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials

Author

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barilà, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Katia Mancuso, Davide Nappi, Sonia Morè, Elena Rivolti, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Emilia Cotzia, Giuseppe Pietrantuono, Angela Maria Quinto, Valeria Amico, Nicola Di Renzo, Marta Coscia, Monica Galli, Valerio De Stefano, Maria Teresa Petrucci, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, and Massimo Gentile

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Not available.

Published
2024
Full Text
View/download PDF

3. Target Therapies for Systemic Mastocytosis: An Update

Author

Mariarita Sciumè, Claudio De Magistris, Nicole Galli, Eleonora Ferretti, Giulia Milesi, Pasquale De Roberto, Sonia Fabris, and Federica Irene Grifoni

Subjects
systemic mastocytosis, target therapy, midostaurin, imatinib, avapritinib, Medicine, Pharmacy and materia medica, RS1-441
Abstract

Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MCs) in extra-cutaneous organs. It could be divided into indolent SM, smoldering SM, SM with an associated hematologic (non-MC lineage) neoplasm, aggressive SM, and mast cell leukemia. SM is generally associated with the presence of a gain-of-function somatic mutation in KIT at codon 816. Clinical features could be related to MC mediator release or to uncontrolled infiltration of MCs in different organs. Whereas indolent forms have a near-normal life expectancy, advanced diseases have a poor prognosis with short survival times. Indolent forms should be considered for symptom-directed therapy, while cytoreductive therapy represents the first-line treatment for advanced diseases. Since the emergence of tyrosine kinase inhibitors (TKIs), KIT inhibition has been an attractive approach. Initial reports showed that only the rare KITD816V negative cases were responsive to first-line TKI imatinib. The development of new TKIs with activity against the KITD816V mutation, such as midostaurin or avapritinib, has changed the management of this disease. This review aims to focus on the available clinical data of therapies for SM and provide insights into possible future therapeutic targets.

Published
2022
Full Text
View/download PDF

4. Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort

Author

Daniele Cattaneo, Cristina Bucelli, Alfredo Marchetti, Marta Lionetti, Elisa Fermo, Valentina Bellani, Claudio De Magistris, Akihiro Maeda, Alessio Marella, Massimo Primignani, Dario Consonni, Umberto Gianelli, Antonino Neri, Luca Baldini, Niccolò Bolli, and Alessandra Iurlo

Subjects
Hematology, General Medicine
Published
2023
Full Text
View/download PDF

5. Splenomegaly: Dare to think rare

Author

Natalia Scaramellini, Giorgio Croci, Claudio De Magistris, Daniele Lello Panzieri, Elena Cassinerio, Alessia Marcon, Fabio Nascimbeni, Antonella Quarta, Maria Domenica Cappellini, and Irene Motta

Subjects
Splenomegaly, Humans, Hematology
Published
2022
Full Text
View/download PDF

6. Successful Chemical Synovectomy in a Patient with Acquired von Willebrand Syndrome with Chronic Synovitis Due to Recurrent Knee Hemarthrosis: A Case Report

Author

Roberta Gualtierotti, Claudio De Magistris, Eugenia Biguzzi, Jacopo Acquati Lozej, Alessandra Iurlo, Luigi Piero Solimeno, and Flora Peyvandi

Subjects
Settore MED/09 - Medicina Interna, Rheumatology, Hemarthrosis, Settore MED/33 - Malattie Apparato Locomotore, Immunology and Allergy, Acquired von Willebrand syndrome, Chemical synovectomy, Settore MED/15 - Malattie del Sangue
Abstract

Acquired von Willebrand syndrome (AVWS) is a rare, non-hereditary bleeding disorder related to heterogeneous medical conditions such as hematological malignancies and cardiovascular and autoimmune diseases. We describe the clinical course of a 62-year-old man with polycythemia vera who experienced post-traumatic knee and leg swelling due to hemarthrosis. He was treated at another center with low molecular weight heparin due to misdiagnosed deep vein thrombosis further exacerbating the ongoing bleeding. At our center, he was diagnosed with AVWS with reduced von Willebrand factor (VWF):GPIbR plasma activity and loss of high molecular weight multimers (HMWM). He was treated with compressive bandages with resolution. Five months later, on clinical recurrence of knee and leg swelling, knee ultrasound scan showed the presence of chronic synovitis and a hemorrhagic Baker's cyst with signs of rupture. The treatment consisted of chemical synovectomy with rifampicin and steroids preceded by systemic replacement therapy using plasma-derived factor VIII-VWF concentrate. At the end of the treatment cycle, our patient reported complete resolution of knee pain and restoration of joint range of motion and function. Ultrasound evaluation confirmed complete resolution of knee capsule distension and Baker's cyst. Hemarthrosis is an anecdotal presentation of AVWS and chemical synovectomy was successful in treating this complication. A multidisciplinary approach allowed an effective management of this rare complication.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results